NicOx SA (COX.PA) Receives Positive Opinion for European Orphan Drug Designation for Naproxcinod for the Treatment of Duchenne Muscular Dystrophy
9/11/2013 9:35:16 AM
Nicox S.A. (NYSE Euronext Paris: COX) today announced that it has received a
positive opinion from the European Union Committee for Orphan Medicinal Products
(COMP) recommending orphan drug designation for naproxcinod, a CINOD
(Cyclooxygenase-Inhibiting Nitric Oxide-Donating) anti-inflammatory candidate,
for the treatment of Duchenne Muscular Dystrophy (DMD). The orphan drug
designation allows companies to benefit from a number of incentives, including a
10-year market exclusivity post-approval, scientific advice and fee reductions.
Final approval of the opinion on orphan designation is expected from the
European Commission in the coming months. Naproxcinod has shown promising
preclinical results in models of muscular dystrophy.
Help employers find you! Check out all the jobs and post your resume.
comments powered by